GSK-2636771 is an inhibitor of the p110β isoform of PI3K. GSK-2636771 displays anticancer chemotherapeutic activity in PTEN-deficient cancers such as glioblastomas, prostate cancers, and endometrial cancers. This compound is currently in clinical trials.
| Cas No. | 1372540-25-4 |
|---|---|
| Purity | ≥98.5% |
| Formula | C22H22F3N3O3 |
| Formula Wt. | 433.42 |
| IUPAC Name | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid |
| Solubility | Soluble in DMSO, and water with 1 eq. of base |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | G7346 Info Sheet PDF |
|---|---|
| Brochures | PI3K-Akt-mTORC Pathway Booklet |
Weigelt B, Warne PH, Lambros MB, et al. PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.
